S&P 500
(1.02%) 5 099.96 points
Dow Jones
(0.40%) 38 240 points
Nasdaq
(2.03%) 15 928 points
Oil
(0.11%) $83.66
Gas
(-1.16%) $1.619
Gold
(0.30%) $2 349.60
Silver
(-0.43%) $27.52
Platinum
(0.42%) $924.40
USD/EUR
(0.32%) $0.935
USD/NOK
(0.67%) $11.02
USD/GBP
(0.13%) $0.800
USD/RUB
(-0.07%) $92.11

Realaus laiko atnaujinimai Pfizer Inc [PFE.DE]

Birža: XETRA Sektorius: Pharmaceuticals Pramonė: Drug Manufacturers—General
Upcoming Earnings Alert

Quarter results tomorrow
(bmo 2024-04-29)

Expected move: +/- 0.00%

Atnaujinta26 bal. 2024 @ 18:35

-0.25% 23.79

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 18:35):

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands...

Stats
Šios dienos apimtis 70 820.00
Vidutinė apimtis 92 922.00
Rinkos kapitalizacija 134.31B
EPS €0 ( 2024-01-30 )
Kita pelno data ( €0 ) 2024-04-29
Last Dividend €0.410 ( 2023-07-27 )
Next Dividend €0 ( N/A )
P/E 69.96
ATR14 €0.0470 (0.20%)

Tūris Koreliacija

Ilgas: 0.03 (neutral)
Trumpas: 0.59 (weak)
Signal:(51.925) Neutral

Pfizer Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Pfizer Inc Koreliacija - Valiuta/Žaliavos

The country flag 0.07
( neutral )
The country flag 0.14
( neutral )
The country flag 0.00
( neutral )
The country flag 0.19
( neutral )
The country flag -0.44
( neutral )
The country flag -0.11
( neutral )

Pfizer Inc Finansinės ataskaitos

Annual 2023
Pajamos: €58.50B
Bruto pelnas: €33.54B (57.34 %)
EPS: €0.380
FY 2023
Pajamos: €58.50B
Bruto pelnas: €33.54B (57.34 %)
EPS: €0.380
FY 2022
Pajamos: €100.33B
Bruto pelnas: €65.99B (65.77 %)
EPS: €5.63
FY 2021
Pajamos: €81.29B
Bruto pelnas: €50.47B (62.08 %)
EPS: €3.95

Financial Reports:

No articles found.

Pfizer Inc Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
€0.400
(N/A)
€0.400
(N/A)
€0.410
(N/A)
€0.410
(N/A)
€0.410
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)

Pfizer Inc Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 6.07 - average (69.29%) | Divividend Growth Potential Score: 4.08 - Stable (18.42%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend €0.325 2008-01-11
Last Dividend €0.410 2023-07-27
Next Dividend €0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 68 --
Total Paid Out €20.64 --
Avg. Dividend % Per Year 0.00% --
Score 3.7 --
Div. Sustainability Score 6.07
Div.Growth Potential Score 4.08
Div. Directional Score 5.07 --
Next Divdend (Est)
(2024-07-08)
€0.419 Estimate 22.38 %
Dividend Stability
0.60 Average
Dividend Score
3.70
Pay Frequency
Quarterly
Yearly Payout
Year Amount Yield

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for XETRA

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
LOM.DE Ex Dividend Knight 2023-08-31 Quarterly 0 0.00%
2GB.DE Ex Dividend Junior 2023-06-14 Annually 0 0.00%
V6C.DE Ex Dividend Junior 2023-06-01 Annually 0 0.00%
ELG.DE Ex Dividend Knight 2023-05-11 Annually 0 0.00%
NTH.DE Ex Dividend Knight 2023-08-25 Quarterly 0 0.00%
AEIN.DE Ex Dividend Knight 2023-06-14 Annually 0 0.00%
GOB.DE Ex Dividend Knight 2023-06-12 Sporadic 0 0.00%
PSQ.F Ex Dividend Knight 2023-08-23 Semi-Annually 0 0.00%
BLQA.DE Ex Dividend Knight 2023-09-07 Quarterly 0 0.00%
INH.DE Ex Dividend Knight 2023-05-18 Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.03671.5009.2710.00[0 - 0.5]
returnOnAssetsTTM0.009471.2009.6810.00[0 - 0.3]
returnOnEquityTTM0.02221.500-0.864-1.296[0.1 - 1]
payoutRatioTTM4.31-1.00010.00-10.00[0 - 1]
currentRatioTTM0.9070.800-0.467-0.373[1 - 3]
quickRatioTTM0.5830.800-1.279-1.023[0.8 - 2.5]
cashRatioTTM0.05971.500-0.779-1.169[0.2 - 2]
debtRatioTTM0.313-1.5004.79-7.18[0 - 0.6]
interestCoverageTTM0.5511.000-0.907-0.907[3 - 30]
operatingCashFlowPerShareTTM1.5552.009.4810.00[0 - 30]
freeCashFlowPerShareTTM0.8562.009.5710.00[0 - 20]
debtEquityRatioTTM0.796-1.5006.82-10.00[0 - 2.5]
grossProfitMarginTTM0.4791.0005.365.36[0.2 - 0.8]
operatingProfitMarginTTM0.02081.000-1.584-1.584[0.1 - 0.6]
cashFlowToDebtRatioTTM0.1231.000-0.429-0.429[0.2 - 2]
assetTurnoverTTM0.2580.800-1.612-1.289[0.5 - 2]
Total Score6.07

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM66.391.0003.390[1 - 100]
returnOnEquityTTM0.02222.50-0.555-1.296[0.1 - 1.5]
freeCashFlowPerShareTTM0.8562.009.7110.00[0 - 30]
dividendYielPercentageTTM6.481.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM1.5552.009.4810.00[0 - 30]
payoutRatioTTM4.311.50010.00-10.00[0 - 1]
pegRatioTTM-2.391.500-10.000[0.5 - 2]
operatingCashFlowSalesRatioTTM0.1491.0008.780[0.1 - 0.5]
Total Score4.08

Pfizer Inc

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Apie Signalai gyvai

Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.

Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.